After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.

Pfizer's COVID revenues include direct sales and alliance revenues from its partner, BioNTech BNTX, for Comirnaty and product revenues from its oral antiviral pill for COVID-19, Paxlovid.

The Food and Drug Administration (FDA) updated its emergency use authorization (EUA) for Paxlovid (nirmatrelvir/ritonavir) in 2022. This change has allowed people who ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a U.S. national stockpile delivery led to $2.7 billion in sales for the drug, Pfizer said Tuesday.

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year.

5, 2021, in New York. (AP Photo/Mark Lennihan, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] A boost from COVID-19 treatment sales helped bush Pfizer to a ...